Upamostat
| CAS No. | 590368-25-5 | Cat. No. | BCP23974 |
| Name | Upamostat | ||
| Synonyms | WX 671;WX671;WX-671;Mesupron; | ||
| Formula | C32H47N5O6S | M. Wt | 629.81 |
| Description | Upamostat, also known as Mesupron and WX-671, is an orally bioavailable, 3-amidinophenylalanine-derived, second generation serine protease inhibitor prodrug targeting the human urokinase plasminogen activator (uPA) system with potential antineoplastic and antimetastatic activities. After oral administration, serine protease inhibitor WX-671 is converted to the active Nα-(2,4,6-triisopropylphenylsulfonyl)-3-amidino-(L)-phenyla lanine-4-ethoxycarbonylpiperazide (WX-UK1), which inhibits several serine proteases, particularly uPA; inhibition of uPA may result in the inhibition of tumor growth and metastasis. | ||
| Pathways | Protease/Metabolic Enzyme | ||
| Targets | Serine Protease | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.